Skip to main content


Fig. 3 | BMC Cancer

Fig. 3

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Fig. 3

PAK1 knock-down (KD) inhibits expression of AKT and HIF1α. Expression of phospho-AKT (pAKT) was significantly reduced in the PAK1 KD clones: 2.05 and 2.10 (PANC-1 (a)); and 3.09 and 3.12 (MiaPaCa-2 (b)), compared to the negative controls (NC), as assessed by western blot. HIF1α expression was reduced in PANC-1 (c) and MiaPaCa-2 (d) PAK1 KD clones under normoxia and hypoxia (1 % O2) conditions. The data represent mean ± SEM, summarised from three independent experiments. * p < 0.05; ** p < 0.01, *** p < 0.001, compared to either NC clone (only the higher p value of the two is presented)

Back to article page